Drug Trial Radar · NCT02492841
Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth
Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Apr 2014
Primary completion
Apr 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Universidad de los Andes, ChileAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 7 years, up to 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: Dental caries is considered an oral health problem worldwide. In Chile the last national epidemiological study (2007) showed a national prevalence of dental caries in children 6 years (70.3%) and 12 (62.5%). Direct pulp capping is a preventive dental therapy, keeps the vitality of the tooth using some inductive materials mineralized tissue formation. Objective: The main objective of this study is to evaluate the effectiveness of two innovative direct pulp capping materials; Biodentine compared MTA and calcium hydroxide in the maintenance of pulp vitality in teeth permanent molars.
Conditions
- Caries
- Dental Pulp Exposure
Interventions
Mineral trioxide aggregateDrug
Mineral trioxide aggregate
Calcium hydroxideDrug
Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
BiodentineDrug
Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parameters Evaluated After TreatmentTime frame: 3 months, 6 moths and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centro de Salud de San Bernardo Universidad de Los Andes
Santiago, Chile
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.